MedTrace Logo

Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC

NCT02952469 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-09-03

No results posted yet for this study

Summary

The purpose of this Radioactive Drug Research Committee (RDRC) study is to collect initial data regarding biodistribution, reproducibility, and dosimetry for the radiotracer Ga-68 PSMA-HBED-CC, an agent which may be useful for the early detection of metastatic prostate cancer. Investigators will use a test and re-test design in all patients to determine reproducibility of lesion detection and signal intensity, and will include dynamic imaging in some patients for the purposes of dosimetry. Patients with known metastatic prostate cancer will be recruited and imaged on two occasions within the course of 15 days.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

(68Ga)PSMA-HBED-CC

Experimental radiotracer for imaging prostate cancer

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • Janet Pollard, M.D. · University of Iowa

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-14
Primary Completion
2022-04-25
Completion
2022-04-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02952469 on ClinicalTrials.gov